Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1992 Jul 18;305(6846):173–176. doi: 10.1136/bmj.305.6846.173

Hodgkin's lymphoma. II: Treatment and delayed morbidity.

P Carde 1
PMCID: PMC1883215  PMID: 1489407

Full text

PDF
173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonadonna G., Santoro A., Gianni A. M., Viviani S., Siena S., Bregni M., Zucali R., Lombardi F., Bonfante V., Gianni L. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol. 1991 Jan;2 (Suppl 1):9–16. doi: 10.1093/annonc/2.suppl_1.9. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P., Santoro A. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv. 1985;4(2):439–458. [PubMed] [Google Scholar]
  3. Carde P., Burgers J. M., Henry-Amar M., Hayat M., Sizoo W., Van der Schueren E., Monconduit M., Noordijk E. M., Lustman-Marechal J., Tanguy A. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988 Feb;6(2):239–252. doi: 10.1200/JCO.1988.6.2.239. [DOI] [PubMed] [Google Scholar]
  4. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  5. Cimino G., Biti G. P., Anselmo A. P., Maurizi Enrici R., Bellesi G. P., Bosi A., Cionini L., Mungai V., Papa G., Ponticelli P. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease. J Clin Oncol. 1989 Jun;7(6):732–737. doi: 10.1200/JCO.1989.7.6.732. [DOI] [PubMed] [Google Scholar]
  6. Clarke R. J., Mayo G., Price P., FitzGerald G. A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991 Oct 17;325(16):1137–1141. doi: 10.1056/NEJM199110173251605. [DOI] [PubMed] [Google Scholar]
  7. Cosset J. M., Henry-Amar M., Carde P., Clarke D., Le Bourgeois J. P., Tubiana M. The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the Institut Gustave-Roussy. Hematol Oncol. 1984 Jan-Mar;2(1):33–43. doi: 10.1002/hon.2900020105. [DOI] [PubMed] [Google Scholar]
  8. Cosset J. M., Henry-Amar M., Meerwaldt J. H. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol. 1991 Feb;2 (Suppl 2):77–82. doi: 10.1093/annonc/2.suppl_2.77. [DOI] [PubMed] [Google Scholar]
  9. Cosset J. M., Henry-Amar M., Pellae-Cosset B., Carde P., Girinski T., Tubiana M., Hayat M. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):447–449. doi: 10.1016/0360-3016(91)90794-5. [DOI] [PubMed] [Google Scholar]
  10. Dionet C., Oberlin O., Habrand J. L., Vilcoq J., Madelain M., Dutou L., Bey P., Lefur R., Thierry P., Le Floch O. Initial chemotherapy and low-dose radiation in limited fields in childhood Hodgkin's disease: results of a joint cooperative study by the French Society of Pediatric Oncology (SFOP) and Hôpital Saint-Louis, Paris. Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):341–346. doi: 10.1016/s0360-3016(98)90013-x. [DOI] [PubMed] [Google Scholar]
  11. Ekert H., Waters K. D., Smith P. J., Toogood I., Mauger D. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol. 1988 Dec;6(12):1845–1850. doi: 10.1200/JCO.1988.6.12.1845. [DOI] [PubMed] [Google Scholar]
  12. Haybittle J. L., Hayhoe F. G., Easterling M. J., Jelliffe A. M., Bennett M. H., Vaughan Hudson G., Vaughan Hudson B., MacLennan K. A. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet. 1985 Apr 27;1(8435):967–972. doi: 10.1016/s0140-6736(85)91736-2. [DOI] [PubMed] [Google Scholar]
  13. Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol. 1990 Dec;17(6):758–768. [PubMed] [Google Scholar]
  14. Hoerni B., Orgerie M. B., Eghbali H., Blanc C. M., David B., Rojouan J., Zittoun R. Nouvelle association d'épirubicine, bléomycine, vinblastine et prednisone (EBVP II) avant radiotherapie dans les stades localisés de maladie de Hodgkin. Essai de phase II chez 50 malades. Bull Cancer. 1988;75(8):789–794. [PubMed] [Google Scholar]
  15. Hohl R. J., Schilsky R. L. Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun;3(2):331–343. [PubMed] [Google Scholar]
  16. Hoppe R. T., Horning S. J., Hancock S. L., Rosenberg S. A. Current Stanford clinical trials for Hodgkin's disease. Recent Results Cancer Res. 1989;117:182–190. doi: 10.1007/978-3-642-83781-4_19. [DOI] [PubMed] [Google Scholar]
  17. Hoppe R. T. Radiation therapy in the management of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6):704–715. [PubMed] [Google Scholar]
  18. Horning S. J., Hoppe R. T., Hancock S. L., Rosenberg S. A. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol. 1988 Dec;6(12):1822–1831. doi: 10.1200/JCO.1988.6.12.1822. [DOI] [PubMed] [Google Scholar]
  19. Horwich A. The management of early Hodgkin's disease. Blood Rev. 1990 Sep;4(3):181–186. doi: 10.1016/0268-960x(90)90046-u. [DOI] [PubMed] [Google Scholar]
  20. Jagannath S., Dicke K. A., Armitage J. O., Cabanillas F. F., Horwitz L. J., Vellekoop L., Zander A. R., Spitzer G. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986 Feb;104(2):163–168. doi: 10.7326/0003-4819-104-2-163. [DOI] [PubMed] [Google Scholar]
  21. Jégou B., Velez de la Calle J. F., Bauché F. Protective effect of medroxyprogesterone acetate plus testosterone against radiation-induced damage to the reproductive function of male rats and their offspring. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8710–8714. doi: 10.1073/pnas.88.19.8710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kessinger A., Armitage J. O., Smith D. M., Landmark J. D., Bierman P. J., Weisenburger D. D. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood. 1989 Sep;74(4):1260–1265. [PubMed] [Google Scholar]
  23. Longo D. L., Glatstein E., Duffey P. L., Young R. C., Hubbard S. M., Urba W. J., Wesley M. N., Raubitschek A., Jaffe E. S., Wiernik P. H. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991 Jun;9(6):906–917. doi: 10.1200/JCO.1991.9.6.906. [DOI] [PubMed] [Google Scholar]
  24. Longo D. L., Russo A., Duffey P. L., Hubbard S. M., Glatstein E., Hill J. B., Jaffe E. S., Young R. C., DeVita V. T., Jr Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol. 1991 Feb;9(2):227–235. doi: 10.1200/JCO.1991.9.2.227. [DOI] [PubMed] [Google Scholar]
  25. Mauch P., Tarbell N., Weinstein H., Silver B., Goffman T., Osteen R., Zajac A., Coleman C. N., Canellos G., Rosenthal D. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988 Oct;6(10):1576–1583. doi: 10.1200/JCO.1988.6.10.1576. [DOI] [PubMed] [Google Scholar]
  26. Mead G. M., Harker W. G., Kushlan P., Rosenberg S. A. Single agent palliative chemotherapy for end-stage Hodgkin's disease. Cancer. 1982 Sep 1;50(5):829–835. doi: 10.1002/1097-0142(19820901)50:5<829::aid-cncr2820500504>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  27. Nemunaitis J., Rabinowe S. N., Singer J. W., Bierman P. J., Vose J. M., Freedman A. S., Onetto N., Gillis S., Oette D., Gold M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991 Jun 20;324(25):1773–1778. doi: 10.1056/NEJM199106203242504. [DOI] [PubMed] [Google Scholar]
  28. O'Reilly S. E., Hoskins P., Klimo P., Connors J. M. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol. 1991 Jan;2 (Suppl 1):17–23. doi: 10.1093/annonc/2.suppl_1.17. [DOI] [PubMed] [Google Scholar]
  29. Pavlovsky S., Maschio M., Santarelli M. T., Muriel F. S., Corrado C., Garcia I., Schwartz L., Montero C., Sanahuja F. L., Magnasco O. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988 Nov 16;80(18):1466–1473. doi: 10.1093/jnci/80.18.1466. [DOI] [PubMed] [Google Scholar]
  30. Peckham M. J., Ford H. T., McElwain T. J., Harmer C. L., Atkinson K., Austin D. E. The results of radiotherapy for Hodgkins' disease. Br J Cancer. 1975 Sep;32(3):391–400. doi: 10.1038/bjc.1975.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ratain M. J., Rowley J. D. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992 Feb;3(2):107–111. doi: 10.1093/oxfordjournals.annonc.a058121. [DOI] [PubMed] [Google Scholar]
  32. Santoro A., Bonadonna G., Valagussa P., Zucali R., Viviani S., Villani F., Pagnoni A. M., Bonfante V., Musumeci R., Crippa F. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27–37. doi: 10.1200/JCO.1987.5.1.27. [DOI] [PubMed] [Google Scholar]
  33. Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139–143. doi: 10.7326/0003-4819-96-2-139. [DOI] [PubMed] [Google Scholar]
  34. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev. 1991 Mar;18(1):21–53. doi: 10.1016/0305-7372(91)90003-i. [DOI] [PubMed] [Google Scholar]
  35. Speyer J. L., Green M. D., Zeleniuch-Jacquotte A., Wernz J. C., Rey M., Sanger J., Kramer E., Ferrans V., Hochster H., Meyers M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992 Jan;10(1):117–127. doi: 10.1200/JCO.1992.10.1.117. [DOI] [PubMed] [Google Scholar]
  36. Tubiana M., Henry-Amar M., Carde P., Burgers J. M., Hayat M., Van der Schueren E., Noordijk E. M., Tanguy A., Meerwaldt J. H., Thomas J. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989 Jan;73(1):47–56. [PubMed] [Google Scholar]
  37. Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES